Alcohol abstinence drug acamprosate deemed "not approvable" by FDA, Forest says July 2. The agency is requesting "at least" one additional U.S. safety and efficacy trial and further pharmacokinetic analyses and pre-clinicals. The NDA was based on three European studies from the late-1980s to mid-1990s and one U.S. trial that did not demonstrate efficacy over placebo (1"The Pink Sheet" May 20, p. 25). Forest and Lipha expect a meeting with FDA in August. The NDA was filed in December 2001 and received a priority review...
You may also be interested in...
A subgroup analysis of European trial data for Forest/Lipha's acamprosate would help clarify whether trends seen in certain U.S. clinical trial subpopulations are meaningful, FDA's Psychopharmacologic Drugs Advisory Committee suggested May 10
Moderna is speculated to be in talks with Indian firms, including Wockhardt and a Tata group company, for manufacturing its COVID-19 vaccine. A deal in India could help the company meet its obligation to supply COVAX but Moderna is likely to choose its partner carefully.
Trade group AdvaMed should be consulted on how to implement the Defense Production Act to boost testing and PPE production, CEO Scott Whitaker said in a letter to President Biden.